News 67% of PTSD sufferers drop diagnosis in first MDMA Phase 3 trial Following the successful MAPS study, MDMA-assisted therapy moves closer to becoming approved by the US FDA Natalia Buendia CalvilloMay 4, 2021
Industry update US FDA unveils plan to gather ‘real-world’ data to fill CBD research gaps After two years of delaying regulations, the agency looks to improve data-gathering methods on CBD product safety Jared GnamJanuary 11, 2021
Industry update Dousing strawberries in CBD oil reduces mould, extends shelf life: study Research from the University of South Florida suggests CBD has promising potential as an antimicrobial treatment for fresh produce Jared GnamDecember 10, 2020
CBD FDA issues cannabis research guidelines as CBD industry still hangs in limbo Vermont cannabis lawyer Timothy Fair calls FDA's two-year delay on CBD regulations 'beyond absurd' Jared GnamJuly 24, 2020
Industry update Charlotte’s Web backs study on health outcomes of CBD Third-party study aims to provide U.S. FDA with new science to expedite creation of a regulatory framework Jared GnamJune 10, 2020
Canada If your company is producing hand sanitizer to fight COVID-19, make sure it’s alcohol-based Valens and Neptune’s formulations are in line with official guidance, while others are not Nick LabaApril 9, 2020
Enforcement FDA’s update on CBD regulations is ‘frankly absurd’ Report only offers industry small amount of reassurance and regulatory guidelines, says cannabis lawyer Michelle GamageMarch 6, 2020
CBD Four CBD companies poised to take advantage of U.S. policy shift [Sponsored article] A new U.S. House bill tabled last week would open up the market for these four CBD players Jared GnamJanuary 21, 2020
CBD US House introduces bill to allow sale of CBD-infused food and drink The bipartisan bill would allow for hemp-derived CBD to be sold as a dietary supplement Jared GnamJanuary 17, 2020
Medical and Pharmaceutical U.S. FDA gives rare designation to THC cancer drug in clinical trials Tetra Bio-Pharma’s stock continues to rise after announcing more trials at no additional cost to shareholders Nick LabaDecember 4, 2019